-
16978-50A potent, selective ATP-competitive inhibitor of mTOR (IC<sub>50</sub> = 0.8 nM) inhibits proliferation of A549 (IC<sub>50</sub> = 53 nM) and H838 cells (IC<sub>50</sub> = 20 nM) as well as several human tumor xenografts (>65% at 20 mg/kg).
-
11588-1AZD 8330 is a selective allosteric inhibitor of MEK1/2 (IC50 = 7 nM). It blocks phosphorylation of ERK1/2 and inhibits proliferation of certain cancer cells.
-
11588-10AZD 8330 is a selective allosteric inhibitor of MEK1/2 (IC50 = 7 nM). It blocks phosphorylation of ERK1/2 and inhibits proliferation of certain cancer cells.
-
11588-5AZD 8330 is a selective allosteric inhibitor of MEK1/2 (IC50 = 7 nM). It blocks phosphorylation of ERK1/2 and inhibits proliferation of certain cancer cells.
-
11588-50AZD 8330 is a selective allosteric inhibitor of MEK1/2 (IC50 = 7 nM). It blocks phosphorylation of ERK1/2 and inhibits proliferation of certain cancer cells.
-
16237-1An irreversible inhibitor of EGFR sensitizing and T790M resistance mutations (IC<sub>50</sub>s = 15-17 nM) while sparing the wild-type EGFR (IC<sub>50</sub> = 480 nM) inhibits tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg.
-
16237-10An irreversible inhibitor of EGFR sensitizing and T790M resistance mutations (IC<sub>50</sub>s = 15-17 nM) while sparing the wild-type EGFR (IC<sub>50</sub> = 480 nM) inhibits tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg.
-
16237-5An irreversible inhibitor of EGFR sensitizing and T790M resistance mutations (IC<sub>50</sub>s = 15-17 nM) while sparing the wild-type EGFR (IC<sub>50</sub> = 480 nM) inhibits tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg.
-
16237-50An irreversible inhibitor of EGFR sensitizing and T790M resistance mutations (IC<sub>50</sub>s = 15-17 nM) while sparing the wild-type EGFR (IC<sub>50</sub> = 480 nM) inhibits tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg.
-
10702-1A selective JAK2 inhibitor that blocks signaling (IC50 = 58 nM at 5 mM ATP) and proliferation of JAK2-expressing cell lines (GI50 = 60 nM) displays good pharmacokinetics in vivo, inhibits STAT3 and STAT5 activation in vivo, and suppresses
-
10702-10A selective JAK2 inhibitor that blocks signaling (IC50 = 58 nM at 5 mM ATP) and proliferation of JAK2-expressing cell lines (GI50 = 60 nM) displays good pharmacokinetics in vivo, inhibits STAT3 and STAT5 activation in vivo, and suppresses
-
10702-5A selective JAK2 inhibitor that blocks signaling (IC50 = 58 nM at 5 mM ATP) and proliferation of JAK2-expressing cell lines (GI50 = 60 nM) displays good pharmacokinetics in vivo, inhibits STAT3 and STAT5 activation in vivo, and suppresses